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KEY POINTS
 Identifying patients at high risk for percutaneous coronary intervention (PCI) involves a synthesis
of a patient comorbidities, hemodynamic status, and lesion characteristics.
 Mechanical circulatory support devices are used in high-risk PCI to augment cardiac output and
reduce myocardial oxygen demand during coronary intervention.
 The use of mechanical circulatory support devices allows more complete revascularization and
facilitates procedures that previously may not have been technically feasible.
 Prospective randomized trials to date have not shown a benefit for the routine use of mechanical
circulatory support in patients with low ejection fraction and a high burden of coronary disease.
 Further research is required to identify groups that will receive the maximal benefit of
mechanical circulatory support in high-risk PCI.

INTRODUCTION
Coronary artery disease remains a leading
worldwide cause of morbidity and mortality.1
As medical and interventional therapies available to patients with atherosclerotic heart disease have improved, the number of patients
surviving index coronary events has increased
considerably.2 The care of this older, more medically and anatomically complex group of patients has resulted in an increasing number of
patients with indications for coronary revascularization who are at high risk of periprocedural hemodynamic collapse and increased morbidity
and mortality.3

Concurrently, the technology available to
perform complex percutaneous coronary interventions (PCIs) has dramatically improved with
the advent of coronary guides and guide extensions, specialized coronary wires, atherectomy
devices, lower profile balloons and stents, intravascular imaging, specialized equipment for
chronic total occlusions (CTOs), and percutaneous mechanical circulatory support (MCS) devices.4 Patients who previously may not have
been offered coronary revascularization
because of technical factors or risk associated
with cardiac surgery can now be considered
for percutaneous revascularization. A clinical
case that exemplifies this patient population is
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a 66-year-old man with a history of alcohol
abuse who presented to an outside facility
with 1 hour of chest pain. He rapidly developed
hypoxic respiratory failure, and intubation was
complicated by polymorphic ventricular tachycardia and cardiac arrest. Urgent cardiac catheterization was notable for cardiogenic shock
with a cardiac index of 0.9 L/min/m2 and severe
3-vessel coronary artery disease, with CTOs of
the right and left circumflex coronary arteries
and a highly calcific 95% stenosis of the proximal left anterior descending coronary artery
(Fig. 1). The patient was urgently transferred
to a tertiary referral center where, given severe
peripheral arterial disease and cardiogenic
shock, a transcaval Impella 5.0 was placed
(Fig. 2). After stabilization of end-organ function, the patient underwent successful atherectomy and PCI of the left main to left anterior
descending (LAD) artery (Fig. 3). The patient ultimately was successfully weaned from MCS
and discharged to rehabilitation in good condition. In patients such as this and many others
with high-risk lesions and clinical risk, a key
element that has facilitated PCI is the advent
of percutaneous MCS.
Percutaneous MCS in PCI is generally used in
one of 2 clinical settings: patients with acute
myocardial infarctions (MIs) presenting with

cardiogenic shock, and patients electively undergoing planned high-risk PCI.5 In this article, the
use of MCS in elective high-risk PCI is discussed.
Although the use of MCS in high-risk PCI has
been theorized to allow safer, more complete
coronary interventions, MCS in high-risk PCI
has not conclusively been shown to be associated with improved clinical outcomes in prospective randomized clinical trials.6,7 This article
discusses the elements of decision making in
the use of hemodynamic support in high-risk
PCI, the current state of the evidence base for
the use of MCS in high-risk PCI, and a practical
approach to clinical decision making.

DEFINING HIGH-RISK PERCUTANEOUS
CORONARY INTERVENTION
At present, there is no standardized definition of
high-risk PCI. Although risk calculators exist for
both coronary artery bypass grafting (CABG)
and PCI,8,9 experts believe that these calculators
do not adequately capture the complexity of this
patient group.10,11
All proposed definitions of high-risk PCI
incorporate 3 general categories of factors
that, in combination, designate a procedure as
high risk and can justify the use of periprocedural MCS: patient-specific comorbidities,

Fig. 1. Transcaval insertion of an
intravascular micro-axial pump delivering up to 5.0 L/min with (A) simultaneous IVC and aorta angiography,
(B) transcaval puncture, (C) 24
French sheath advancement, and
(D) device positioning.
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Fig. 2. Diagnostic angiography
showing (A) a CTO of the right coronary artery as well as a CTO of the
left circumflex and an eccentric,
calcific stenosis of the proximal left
anterior descending coronary artery
(B, C).

hemodynamic factors, and factors specific to
lesion and procedural technique (Fig. 4).5,12
The relative importance of each of these factors
in this qualitative assessment of procedural risk

Fig. 3. Completion angiogram following intravascular
micro-axial pump supported atherectomy of the proximal left anterior descending coronary artery and bifurcation stenting with the first diagonal branch.

is unknown and remains a future direction for
research.

Patient-Specific Factors
Comorbid diabetes mellitus, chronic lung disease, chronic kidney disease, prior MI, reduced
left ventricular ejection fraction (LVEF), and peripheral arterial disease have all been associated
with worse outcomes in PCI.13–17 Advanced age
and frailty are also associated with higher
morbidity and mortality in patients undergoing
PCI.18 The aggregate of the patient’s underlying
health status is an important factor in determining the patient’s ability to tolerate the
stresses of transient ischemia, bleeding, arrhythmias, and hypotension often encountered in
high-risk PCI. Patients with a lower physiologic
reserve are more likely to incur end-organ
dysfunction and ultimately mortality as a result
of the hemodynamic stress of PCI and should
be more strongly considered for the use of MCS.
Hemodynamic Status
The acuity of the clinical presentation before PCI
remains the strongest predictor of procedural
major adverse events.19 PCI in the setting of
acute coronary syndrome confers a higher risk
of adverse events than elective PCI. Symptomatic heart failure with increased filling pressures
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Fig. 4. Contributing factors in
defining the high-risk PCI patient
group most likely to benefit from
invasive hemodynamic assessment
and the use of MCS. CKD, chronic
kidney disease; DM, diabetes mellitus; LV, left ventricle; PAD, peripheral arterial disease.

reduces the patient’s ability to tolerate prolonged supine positioning and increases the patient’s likelihood of developing further heart
failure decompensation with contrast administration and ischemic insults during PCI. This condition can result in both hemodynamic and
respiratory decompensation.20 Arrhythmias,
including atrial fibrillation and ventricular tachycardia, as well as underlying valvular lesions
affect the patient’s hemodynamic status and
can be exacerbated during PCI.21,22 Of particular note is severe aortic stenosis; patients with
ischemia (caused in PCI during balloon inflations,
atherectomy, and so forth) develop worsening
hypotension because of ventricular stunning in
the face of a high fixed afterload.
To most accurately evaluate a patient’s current
hemodynamic status, right heart catheterization
is performed at the beginning of a high-risk PCI
to characterize the patient’s current filling pressures and hemodynamics. Operators are encouraged to begin all high-risk PCIs with a right heart
catheterization to reevaluate the patient’s filling
pressures and biventricular function because the
patient’s hemodynamic status may have changed
since the last interrogation because of ongoing
medication titration. In addition, when evaluating
the patient’s status at the conclusion of a PCI, it
can be useful to have preprocedural hemodynamics for comparison.

Factors Specific to Lesion and Procedural
Technique
Lesion complexity and anticipated procedural
techniques confer important prognostic information when evaluating the risk and anticipated benefits of a coronary intervention.
Lesions defined empirically as high complexity
include unprotected left main stenosis, heavy
calcified or diffuse disease, true bifurcation lesions (Medina 1/1/1, 1/0/1, and 0/1/1), saphenous vein graft lesions, and CTOs.23,24 Several
risk scores have been validated to quantify
the anatomic complexity and significance of a
patient’s coronary artery disease, including
the Duke Jeopardy score and the Synergy Between PCI with Taxus and CABG (SYNTAX)
score.25,26
The Duke Jeopardy score was first described
by Califf and colleagues25 in an effort to predict
survival based on the distribution and degree of
coronary artery disease. The Duke Jeopardy
score estimates the amount of myocardium at
risk by dividing the coronary tree into 6 anatomic
segments (left anterior descending, first diagonal branch, first septal, left circumflex, first
obtuse marginal, and posterior descending artery). Two points are assigned for each segment
that has a stenosis 70% or greater, with the addition of 2 points for each downstream segment
from a lesion. For example, a significant
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proximal LAD lesion would have a Jeopardy
score of 6 (2 for LAD, 2 for first septal, 2 for diagonal). Jeopardy scores range from 0 to 12,
with a score of 2 conferring a 97% 5-year survival
and a score of 12 conferring a 55% 5 year
survival.
The SYNTAX score was developed to stratify
the anatomic complexity of coronary lesions in
patients with 3-vessel or left main coronary artery disease to guide surgical versus percutaneous revascularization strategy in a clinical
trial.26 Unlike the Duke Jeopardy score, the SYNTAX score includes lesion characteristics such as
calcification, length, ostial location, and bifurcation involvement. In the SYNTAX trial, patients
were divided into tertiles of SYNTAX scores,
with a score of 22 or lower considered low
complexity, 23 to 32 intermediate, and 33 or
greater high complexity. The SYNTAX score
was further refined with the SYNTAX II score,
which combines both anatomic and clinical factors to aid heart team decision making.
Defining high-risk coronary interventions includes an evaluation of anatomic complexity,
as exemplified by the Duke Jeopardy score or
SYNTAX score. In addition, planned procedural
techniques are an important factor in lesion evaluation.27 Use of atherectomy and prolonged
kissing balloon inflations are more likely to
induce significant ischemia and hypotension.28
Use of the retrograde approach in CTO PCI is
also associated with higher hemodynamic stress
than antegrade CTO PCI because of ischemia to
collaterals perfusing the CTO territory and
ischemia in the territory of the donor vessel.29,30
Any lesion involving the last remaining vessel
carries high risk of hemodynamic decompensation when ischemia is induced during angioplasty and in the event of any complication
involving the last remaining vessel.

Maintaining systemic perfusion with a stable cardiac output and mean arterial pressure prevents
the adverse metabolic effects of tissue hypoperfusion that lead to end-organ dysfunction,
morbidity, and mortality.
Myocardial oxygen extraction is an efficient
process with 70% to 80% of oxygen extracted
by myocardial tissue in resting conditions.33
Because myocardial oxygen extraction is unable
to be significantly augmented, changes in
myocardial oxygen delivery are primarily driven
by coronary blood flow. Coronary blood flow is
determined by the systemic pressure, left ventricular end-diastolic pressure, and wall tension.
These factors are controlled by the preload,
afterload, heart rate, contractility, and wall stress
of the ventricle. Imbalance between oxygen supply, as determined by coronary blood flow, and
demand results in myocardial ischemia.34 In general, therapies that reduce afterload or preload,
decrease wall stress, or reduce heart rate
decrease the myocardial oxygen demand of
the ventricle and improve myocardial blood
flow, thus reducing the ischemic burden on the
heart. The abilities of MCS devices to reduce
myocardial oxygen demand and augment coronary blood flow are variable based on the design
of each device.34
The current MCS devices used in high-risk PCI
include the intra-aortic balloon pump (IABP), left
ventricle (LV) to aorta assist devices (Impella 2.5,
Impella CP, Impella 5.0), left atrium to aorta assist
devices (TandemHeart), and venoarterial extracorporeal membrane oxygenation (VA-ECMO).
The variable effect on hemodynamics,
myocardial oxygen consumption, and cardiac
output augmentation of these MCS devices is
summarized in Table 1.

HEMODYNAMIC EFFECTS OF
MECHANICAL CIRCULATORY SUPPORT IN
HIGH-RISK PERCUTANEOUS CORONARY
INTERVENTION

As the first widely used percutaneous MCS device, the IABP has enjoyed high rates of use
because of widespread availability and ease of
use. The IABP has been studied extensively in
acute MI with cardiogenic shock (AMICS). Despite
its continued use in patients presenting with
AMICS, the pivotal IABP-SHOCK II (Intra-aortic
Balloon Support for Myocardial Infarction with
Cardiogenic Shock) trial found the IABP to not
be superior to medical management for the management of cardiogenic shock in patients presenting with acute coronary syndrome.35
Within the realm of elective high-risk PCI,
several observational trials suggested reduced
rates of major adverse cardiac events with
upfront IABP insertion compared with ad hoc

The goal of MCS in high-risk PCI is to reduce
myocardial oxygen consumption, improve
myocardial blood flow, and maintain systemic
perfusion during the procedure.31 Reduced
myocardial oxygen consumption and improved
myocardial blood flow increase the threshold at
which the ventricle becomes ischemic.32 This
condition reduces the adverse effects of myocardial ischemia, including arrhythmias, increased
filling pressures caused by diastolic dysfunction,
and
ultimately
systemic
hypotension.

CURRENT EVIDENCE
Intra-aortic Balloon Pump
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Table 1
Hemodynamic effects of commonly used mechanical circulatory support platforms

Afterload

LVEDP

MAP

CO

Left
Ventricular
Unloading

IABP

Y

Y

[

[

[

Y

0.5

Impella CP
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Y

[

[

[

Y

4.0

Tandem Heart

5

Y

[

[

[

Y

5.0

VA-ECMO

[

[ to 5

[

[

Y

5

7.0

Myocardial
Oxygen
Demand

Maximal
Flow
(L/min)

Abbreviations: CO, cardiac output; LVEDP, left ventricular end-diastolic pressure; MAP, mean arterial pressure.

IABP insertion. This hypothesis was tested in
the Elective Intra-aortic Balloon Conterpulsation During High-risk Percutaneous Coronary
Intervention (BCIS-1) trial.6 The BCIS-1 trial
was the first clinical trial to prospectively study
MCS in elective high-risk PCI in a randomized
fashion. Ultimately, 300 patients were randomized to IABP insertion before high-risk PCI with
balloon pump in place for 4 to 24 hours versus
standard PCI. The composite end point of MI,
death, stroke, or further revascularization at
hospital discharge was not significantly
different between the groups. Routine IABP
use was associated with fewer procedural complications, including periprocedural hypotension and pulmonary edema. However, The
routine IABP group had more minor bleeding
and access site complications than standard
PCI.
Although not powered to examine all-cause
mortality, the BCIS-1 cohort was followed for
long-term all-cause mortality.36 The investigators reported a statistically significant reduction in all-cause mortality in the routine IABP
group at a median of 51 months after the index procedure. The overall mortality for the
cohort was high (33%), reflecting the high-risk
patient population enrolled in the BCIS-1 trial.
The hazard ratio for all-cause mortality in patients with routine IABP placement before PCI
was 0.66, conferring a 34% reduction in allcause mortality compared with the unsupported PCI group.
Overall, elective IABP insertion in high-risk
PCI has a limited role in modern practice.
Upfront IABP may be a reasonable option in patients at particularly high risk of hemodynamic
decompensation with poor vascular access prohibiting larger device insertion.

Impella
The Impella was first introduced in Europe in
2004. In 2008, the Impella 2.5 became available

in the United States, receiving US Food and
Drug Administration (FDA) approval for partial
hemodynamic support in cardiac procedures
not requiring cardiopulmonary bypass.37 Since
its approval, the Impella has been used in a variety of clinical settings, including cardiogenic
shock, acute MI, postcardiotomy syndrome,
and high-risk PCI.38–40 In the subsequent
decade, the device has been iterated, with the
Impella CP and the Impella 5.0 offering superior
cardiac output augmentation and ventricular
unloading. The Impella 2.5, CP, and 5.0 have
now received FDA approval for procedural use
in high-risk PCI as well as in the setting of acute
MI and cardiogenic shock.41
The Impella system was hypothesized to be
superior to IABP in high-risk PCI because of its
greater ability to directly unload the ventricle
and provide continuous cardiac output, with
the Impella 5.0 providing up to 5 L/min
compared with the modest contribution of
0.5 L/min with the IABP. The feasibility of
Impella-supported high-risk PCI was first prospectively evaluated in the the PROTECT I trial
(A prospective feasibility trial investigating the
use of the Impella 2.5 system in patients undergoing high-risk percutaneous coronary intervention).42 Twenty patients undergoing high-risk
PCI, defined as unprotected left main or last
remaining conduit PCI with an LVEF less than
or equal to 35%, underwent Impella 2.5 insertion
before PCI. The primary safety end point of major adverse cardiac events, defined as death, MI,
target vessel revascularization, urgent CABG, or
stroke at 30 days, occurred in 20% of patients.
Two patients had increased periprocedural cardiac enzyme levels meeting the definition of
MI, and 2 patients expired during the 30 days
following the procedure (1 of renal failure leading to cardiac arrest, 1 of sudden cardiac death).
Safety end points were reassuring, with the most
common complication being access site hematomas in 8 out of 20 patients (although, notably,
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hemostasis in this trial was achieved with manual
compression on the 13-Fr arterial access sites).
From an efficacy perspective, all patients were
free from hemodynamic compromise during
their procedures, and angiographic success
was achieved in all patients.
The USpella registry was a multicenter registry designed to evaluate the safety and clinical
outcomes of Impella 2.5 in real-world use.43 In
the USpella registry, high-risk PCI was defined
at the discretion of the operator and included
patients with reduced LV function, complex coronary anatomy, or a high burden of comorbidities. Among the patients who had prophylactic
Impella insertion before high-risk PCI to prevent
hemodynamic compromise, the rate of overall
major adverse cardiac events was 8% with a
96% 30-day survival. The low overall rate of
adverse events was notable in light of the
anatomic complexity and high-risk nature of
the cohort, with an average SYNTAX score of
37%, 56% of patients being surgical turndowns,
66% of patients with New York Heart Association (NYHA) class III or IV symptoms, and 69%
of patients with an ejection fraction less than
35%. Secondary safety outcomes were most
notable for access site complications (3.4%
with access site bleeding requiring transfusion,
3.4% with vascular complications such as dissection or arteriovenous fistula, and 8.6% with hematomas) despite use of endovascular suturebased closure devices. The findings of the
USpella registry were encouraging, with clinical
outcomes showing 90% success rates in multivessel revascularization, improvement in LVEF,
and improvement in NYHA class at discharge.
Overall, these results supported the safety and
feasibility of the use of Impella 2.5 in high-risk
single-vessel and multivessel PCI.
In light of the safety and feasibility of
Impella-supported high-risk PCI in PROTECT I
and findings suggesting benefit in the USpella
registry, the use of the Impella 2.5 versus
IABP was studied in patients undergoing highrisk PCI in the prospective, randomized
controlled PROTECT II study (A prospective,
randomized clinical trial of hemodynamic support with Impella 2.5 versus Intra-Aortic Balloon
Pump in patients undergoing high-risk percutaneous coronary intervention).7 In PROTECT II,
patients were eligible for enrollment if they
were undergoing elective PCI for unprotected
left main, last remaining conduit, or 3-vessel
coronary disease with an LVEF less than or
equal to 35%. Following iliofemoral angiography to verify anatomic appropriateness for
randomization, patients were randomized to

IABP or Impella 2.5 insertion before PCI. The
study was concluded early because of futility
with a total of 452 patients enrolled in the trial.
The patients included in PROTECT II were a
high-risk cohort, with 66% of patients with
NYHA class III or IV symptoms, an average
LVEF of 24%, an average SYNTAX score of 30,
and a mean Society of Thoracic Surgeons
(STS) mortality of 6%. Notably, there were significant differences in the procedural characteristics between the groups randomized to
Impella versus IABP. In procedures among patients randomized to Impella, more contrast
was used, more stents were placed, and atherectomy was used more frequently, with a
greater duration of use and number of runs. In
total, this suggests more extensive and complete coronary revascularization undertaken in
the Impella group than in the IABP group.
PROTECT II did not find significant difference
in the rate of major adverse events, defined as a
composite of all-cause death, MI, stroke, TIA,
revascularization procedure, cardiac or vascular
operation, acute renal insufficiency, severe intraprocedural hypotension requiring therapy, cardiopulmonary
resuscitation,
ventricular
tachycardia requiring cardioversion, new aortic
insufficiency, or angiographic failure of PCI. In
the intention-to-treat analysis, there was a
35.1% major adverse event rate in the Impella
2.5 group versus 40.1% in the IABP group
(P 5 .277). At 90 days, a trend toward lower major adverse events in the Impella group was
noted, although this did not reach statistical significance (P 5 .066). In the per-protocol population, although the 30-day outcomes did not
show a significant difference in major adverse
events, the 90-day major adverse event rate
was significantly lower in the Impella arm (40%
vs 51%; P 5 .023). Patients in the Impella group
were significantly less likely to undergo repeat
revascularization at 90 days compared with the
IABP group. Patients in the study showed significant improvements in LVEF and NYHA class,
although this did not differ between the Impella
and IABP groups.
Overall, the PROTECT II trial was a negative trial. The investigators were not able to
show a difference in the primary outcome of
major adverse events at 30 days between
the patients randomized to Impella versus
IABP. However, these findings must be interpreted in the context of variation in procedural techniques used by operators, with
more extensive rotational atherectomy and
stenting used in the Impella group, likely
because of the patients’ hemodynamic
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stability and perceived ability to tolerate more
aggressive techniques. This hypothesis fits
with the Impella group having higher rates
of periprocedural MI at 30 days and lower
rates of repeat revascularization at 90 days.
In addition, it is unclear whether the highrisk patients in PROTECT II would have been
considered candidates for revascularization in
the absence of MCS.

TandemHeart
The TandemHeart is a left ventricular assist device that is inserted percutaneously and diverts
blood from the left atrium to the femoral artery
at up to 5 L/min. Although the need for left atrial
access via trans-septal puncture has limited
widespread use of this device, several specific
clinical settings make the use of TandemHeart
attractive, including patients with significant
aortic valve disorder or the presence of a left
ventricular thrombus. To date, no randomized
data has been collected regarding the use of
TandemHeart in high-risk PCI.
A prospectively collected single-center registry is the largest published experience
describing the use of TandemHeart in high-risk
PCI.44 In this registry from the Mayo clinic, 64 patients underwent high-risk PCI (LVEF<30% and a
Duke Jeopardy score of 8 or greater) with TandemHeart over a 5-year period. All of the patients were deemed inoperable because of
comorbidities, severity of cardiovascular disease, or both. They were also thought to have
a burden of disease and underlying cardiac
dysfunction to such a degree than an Impella
was considered inadequate periprocedural hemodynamic support. This opinion is reflected in
the baseline characteristics of the patient cohort,
with an average LVEF of 20%, median SYNTAX
score of 33, and median Jeopardy score of 10.
Many of these patients had a recent MI (52%)
complicated by periprocedural cardiogenic
shock (29%), with 45% of patients already having
an IABP in place before intervention.
Despite the high coronary complexity and
high risk of this group, there was a 97% procedural success rate, with left main intervention in
62% of patients and rotational atherectomy in
48% of patients. The 30-day survival in this
high-risk group was 90%. The most common
adverse event was vascular complications
(13% of patients), which largely occurred in
the early experience. The rates of access site
complications decreased markedly with the
routine assessment of iliofemoral access as a
component of case selection and procedure
planning.

A meta-analysis by Briasoulis and colleagues45 included 8 cohort studies with a total
of 205 patients that received TandemHeart for
high-risk PCI. Short-term mortality was 8%,
with major bleeding rates of 3.6%. These outcomes are in line with prior studies given the
high-risk nature of the group being studied.
Overall, the limited data available supports
the use of TandemHeart for MCS in select
high-risk PCI. The high rates of 30-day mortality
and vascular complications may at least in part
be explained by the selection bias among these
observational studies; patients with TandemHeart placement were considered to need
more hemodynamic support than could be provided by an Impella and were likely sicker at
baseline. Despite this, observational data have
shown acceptable safety and feasibility in TandemHeart placement for high-risk PCI in this
inoperable cohort of patients.

Venoarterial Extracorporeal Membrane
Oxygenation
Data for elective high-risk PCI on ECMO are
limited to small single-center experiences. Brilakis and colleagues46 describe their experience
with 5 patients over the course of 5 years who underwent high-risk PCI with ECMO support. The
patients underwent PCI for LV systolic dysfunction (4 patients) or non-ST elevation MI (1 patient).
All interventions were technically successful. The
most common adverse event was vascular access
complications, with 1 pseudoaneurysm requiring
surgical repair and 2 femoral hematomas. All of
their patients lived through 1-year follow-up
with a mean increase in LVEF of 24%.
Similar findings were reported by Barbarash
and colleagues,47 whose experience with elective high-risk PCI with ECMO support included
12 inoperable patients in 1 year. In this group,
all PCI procedures were technically successful
and no in-hospital major adverse events were
observed. There were minimal vascular complications in this case series, with only 1 femoral hematoma reported. Six-month follow-up was
notable for 100% survival, with 2 patients
requiring repeat revascularization.
These single-center reports suggest that
ECMO-supported PCI is feasible and can be performed safely in a highly selected group of patients in experienced centers.

CLINICAL DECISION MAKING
Clinical decision making for patients undergoing
high-risk PCI requires a nuanced understanding
of the complex interplay between patient,
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Fig. 5. Algorithm for decision making in the use of MCS for patients undergoing elective high-risk PCI. Patients
entering the algorithm are those undergoing complex PCI, defined as procedures with high potential for ischemia,
including Duke Jeopardy score greater than 8, last remaining conduit, multivessel obstructive disease, left main
bifurcation with planned atherectomy, retrograde CTO, and those in which an unanticipated complication such
as no reflow or dissection would likely result in hemodynamic collapse. Comorbidities include significant valvular
lesions, prior diagnosis of heart failure, chronic kidney disease, advanced age, and frailty.

lesion, and hemodynamic characteristics as well
as the unique assets and liabilities of the available MCS modalities. Although general conclusions can be drawn from the available
randomized and observational data, these must
be weighed carefully against patient-specific
and procedure-specific considerations. Although
several decision-making algorithms have been
proposed (Fig. 5), none have been prospectively
validated.

Heart Team Approach
The heart team, a multidisciplinary group
convened to discuss complex patient care

decisions, was initially established in clinical trials as a way to select appropriate patients for
interventional versus surgical revascularization.
The heart team is composed at a minimum of
the patient’s primary cardiologist, consulting
interventional cardiologist, and consulting cardiac surgeon. Similar to the manner in which
the heart team has become the standard of
care in aortic valve disease, a heart team for
coronary artery disease has been proposed as
the standard of care for patients being evaluated for high-risk revascularization.12 These
teams use a comprehensive patient assessment
to weigh the relative risks and benefits of
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medical, interventional, or surgical treatment in
a balanced manner and provide unified, clear
recommendations to team members, patients,
and families. In addition to gaining multiple
perspectives on patient management, this
collaborative approach has been shown to be
feasible and promote the application of
evidence-based guidelines to patient care.48

Device Selection
When selecting an MCS modality for high-risk
PCI, it is important to consider the amount of
support needed, adequacy of vascular access,
and device-specific contraindications.
As detailed previously in this article, the
available MCS devices provide different levels
of hemodynamic support, from 0.5 L/min with
IABP to 5 to 6 L/min with VA-ECMO. The cardiac output deficit is one method to determine
the amount of hemodynamic support needed.
In this paradigm, the target cardiac index is
2.2 L/min. The cardiac output deficit is the difference between the target cardiac output
and the cardiac output nadir during the procedure. Although the cardiac output nadir is only
possible to estimate in advance, it can be
approximated based on the patient’s preprocedure hemodynamics as well as an estimate of
the amount of myocardium susceptible to stunning during intervention.
Limitations in vascular access are also an
important consideration when choosing MCS
devices. When femoral arterial access is prohibitive because of peripheral arterial disease,
excessive tortuosity, or small patient habitus,
alternative access (subclavian cutdown or percutaneous axillary access) has been shown to be
feasible and safe for both IABP and Impella
CP.49–51 Severe peripheral arterial disease can
be prohibitive when considering larger sheaths
for blood return for TandemHeart or VAECMO. A novel approach in patients requiring
large-bore access for ECMO, TandemHeart, or
Impella 5.0 with inadequate transfemoral access
is transcaval access, which allows venous transfemoral access with the sheath traversing the inferior vena cava to the abdominal aorta by means
of percutaneous access.52,53 Although this novel
approach has allowed a class of patients who
previously would have been ineligible for MCS
to undergo these procedures, its use is limited
by the small number of operators with adequate
skills for percutaneous transcaval access, management, and removal.
In addition, device-specific contraindications
must be considered when choosing an appropriate MCS platform. With the exception of the

IABP, all MCS platforms require patients to be
able to tolerate systemic anticoagulation.5 Patients with IABP must have a stable rhythm and
a competent aortic valve. The Impella is contraindicated in patients with a mechanical aortic
valve and in the presence of left ventricular
thrombus. It can be difficult to deliver in challenging aortic anatomy, and severe aortic valve
disorder is a relative contraindication. Impella
and TandemHeart require an adequately functioning right ventricle and stable rhythm. The
TandemHeart requires interatrial septum anatomy appropriate for a transseptal puncture. In
addition, VA-ECMO can result in ventricular
distention if the underlying pulsatility of the
ventricle is unable to adequately compete with
the flow from the ECMO circuit.5
With all MCS devices, appropriate patient selection is a prerequisite, and a plan for inability
to separate from the device should be discussed
before MCS insertion with the input of advanced
heart failure and palliative care team members.
It is critical to monitor for complications
including limb ischemia, stroke, and bleeding
as long as the MCS device is in place.

FUTURE DIRECTIONS
As procedural techniques continue to evolve,
the importance of appropriate patient selection
will remain a focus in high-risk PCI. At present,
there are limited data guiding the use and selection of MCS devices. Identifying patients in a systematic fashion that incorporates patient, lesion,
and hemodynamic factors is critical to advancing
clinical research. Clinically, more sophisticated
methods for patient selection will allow identification of the patients who are the most likely
to benefit from intervention as well as those in
whom high-risk PCI is futile.

SUMMARY
Overall, the growing technical complexity of
modern PCI combined with the increasingly comorbid elderly population has resulted in an
expanding group of patients who are considered inoperable or high risk for CABG. These patients, identified based on their comorbidities,
lesion characteristics, and hemodynamic state,
represent a cohort who now are offered highrisk PCI with the use of MCS. To date, clinical
research has not conclusively shown benefit to
the routine use of MCS in prospective randomized controlled trials. Ongoing research focusing
on identifying the appropriate patient/lesion to
derive the greatest benefit with MCS-facilitated
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high-risk PCI is critical to the growth of this field.
In addition, lower-profile, more powerful devices
that maximize hemodynamic benefits while minimizing vascular complications will be critical to
making MCS more efficacious in this group of
patients and interventions.

CLINICS CARE POINTS

 Identifying patients who are high risk for
hemodynamic collapse during elective highrisk PCI requires understanding of patientspecific risk factors, hemodynamics, and
lesion/procedural technique factors. Patients
with multiple comorbidities and
decompensated hemodynamics who require
advanced interventional techniques,
including kissing balloons, atherectomy, or
use of last remaining conduit, should be
strongly considered for MCS.
 The most widely used device in the United
States for high-risk PCI is the IABP. The
IABP has a low risk of vascular complications,
but provides minimal augmentation in
forward systemic flow.
 The LV to aortic assist device (Impella) has
grown in use given the ease of use,
effectiveness of ventricular unloading, and
stable increases in cardiac output with this
device. Vascular complications remain an
important complication limiting the clinical
benefit of these devices.
 The use of TandemHeart and VA-ECMO to
support high-risk PCI has been shown to be
safe and feasible in limited observational
data.
 Future directions for research in high-risk PCI
will likely focus on identifying the group of
patients most likely to benefit from MCSsupported PCI.
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